The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‑kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.
I. W. Flinn
Research Funding - Calistoga Pharmaceuticals
M. T. Schreeder
No relevant relationships to disclose
S. E. Coutre
No relevant relationships to disclose
J. Leonard
No relevant relationships to disclose
N. D. Wagner-Johnston
No relevant relationships to disclose
S. De Vos
No relevant relationships to disclose
R. V. Boccia
No relevant relationships to disclose
L. Holes
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
S. Peterman
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
L. L. Miller
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
A. S. Yu
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals